Liminatus Pharma Inc (LIMN) FinancialsLIMNLiminatus Pharma Inc

In the context of the broader market, LIMN competes directly with industry leaders such as NRSN and JAGX. With a market capitalization of $3.35M, it holds a leading position in the sector. When comparing efficiency, LIMN's gross margin of N/A stands against NRSN's N/A and JAGX's 15.84%. Such benchmarking helps identify whether Liminatus Pharma Inc is trading at a premium or discount relative to its financial performance.

Liminatus Pharma has shown a troubling financial performance with net income losses, including a staggering loss of -$8,168,927 in Q4 2025. The company has had a gross profit of $0 for multiple quarters, indicating severe operational challenges. The current ratio has improved to 1.12 in Q2 2026, suggesting some liquidity, but the overall financial outlook remains weak.